Chen L, Chen X, Cai G, Jiang H, Chen X, Zhang M
MedComm (2020). 2024; 5(11):e783.
PMID: 39492831
PMC: 11531656.
DOI: 10.1002/mco2.783.
Sagi B, Vas T, Csiky B, Nagy J, Kovacs T
Biomedicines. 2024; 12(6).
PMID: 38927457
PMC: 11201004.
DOI: 10.3390/biomedicines12061250.
Sagi B, Kesoi I, Vas T, Csiky B, Nagy J, Kovacs T
BMC Nephrol. 2023; 24(1):261.
PMID: 37661275
PMC: 10476356.
DOI: 10.1186/s12882-023-03308-w.
Nagasawa Y, Misaki T, Ito S, Naka S, Wato K, Nomura R
Int J Mol Sci. 2022; 23(2).
PMID: 35054910
PMC: 8775524.
DOI: 10.3390/ijms23020725.
Sagi B, Kesoi I, Vas T, Csiky B, Nagy J, Kovacs T
BMC Nephrol. 2021; 22(1):390.
PMID: 34809611
PMC: 8609750.
DOI: 10.1186/s12882-021-02596-4.
Low birth weight associates with glomerular area in young male IgA nephropathy patients.
Ruggajo P, Leh S, Svarstad E, Marti H, Vikse B
BMC Nephrol. 2018; 19(1):287.
PMID: 30348100
PMC: 6198493.
DOI: 10.1186/s12882-018-1070-7.
Remission of Hematuria Improves Renal Survival in IgA Nephropathy.
Sevillano A, Gutierrez E, Yuste C, Cavero T, Merida E, Rodriguez P
J Am Soc Nephrol. 2017; 28(10):3089-3099.
PMID: 28592423
PMC: 5619972.
DOI: 10.1681/ASN.2017010108.
The Impact of Kidney Development on the Life Course: A Consensus Document for Action.
Nephron. 2017; 136(1):3-49.
PMID: 28319949
PMC: 5472217.
DOI: 10.1159/000457967.
Icariin ameliorates IgA nephropathy by inhibition of nuclear factor kappa b/Nlrp3 pathway.
Wang X, Li Y, Zhang L, Hao L
FEBS Open Bio. 2017; 7(1):54-63.
PMID: 28097088
PMC: 5221456.
DOI: 10.1002/2211-5463.12161.
DQB1*060101 may contribute to susceptibility to immunoglobulin A nephropathy in southern Han Chinese.
Wang W, Li M, Wang L, Yu X
Front Med. 2016; 10(4):507-516.
PMID: 27896619
DOI: 10.1007/s11684-016-0475-6.
IgA nephropathy in a laboratory worker that progressed to end-stage renal disease: a case report.
Min B, Kim G, Kang T, Yoon C, Cho S, Paek D
Ann Occup Environ Med. 2016; 28:35.
PMID: 27504189
PMC: 4976515.
DOI: 10.1186/s40557-016-0118-z.
Metabolic syndrome and other cardiovascular risk factors associated with the progression of IgA nephropathy.
Kovacs T, Vas T, Kovesdy C, Kesoi I, Sagi B, Wittmann I
Clin Kidney J. 2016; 6(4):395-401.
PMID: 27293567
PMC: 4898329.
DOI: 10.1093/ckj/sfs131.
Low Birth Weight and Risk of Progression to End Stage Renal Disease in IgA Nephropathy--A Retrospective Registry-Based Cohort Study.
Ruggajo P, Svarstad E, Leh S, Marti H, Reisaether A, Vikse B
PLoS One. 2016; 11(4):e0153819.
PMID: 27092556
PMC: 4836690.
DOI: 10.1371/journal.pone.0153819.
The mucosa-kidney axis in IgA nephropathy.
Floege J, Feehally J
Nat Rev Nephrol. 2015; 12(3):147-56.
PMID: 26714580
DOI: 10.1038/nrneph.2015.208.
AOPPs and the progression of kidney disease.
Cao W, Hou F, Nie J
Kidney Int Suppl (2011). 2015; 4(1):102-106.
PMID: 26312159
PMC: 4536974.
DOI: 10.1038/kisup.2014.19.
Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms.
Tian J, Wang Y, Liu X, Zhou X, Li R
Exp Biol Med (Maywood). 2014; 240(7):936-45.
PMID: 25349217
PMC: 4935411.
DOI: 10.1177/1535370214555666.
Continuation of immunosuppressive treatment may be necessary in IgA nephropathy patients with remission of proteinuria: Evaluation by repeat renal biopsy.
Luo M, Yao C, Xu B, Xu Y, Liu W, Feng Y
Exp Ther Med. 2014; 7(3):553-559.
PMID: 24520244
PMC: 3919854.
DOI: 10.3892/etm.2013.1467.
Significance of extracapillary proliferation in IgA-nephropathy patients with regard to clinical and histopathological variables.
Rafieian-Kopaei M, Baradaran A, Nasri H
Hippokratia. 2014; 17(3):258-61.
PMID: 24470738
PMC: 3872464.
Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat.
Wang-Rosenke Y, Khadzhynov D, Loof T, Mika A, Kawachi H, Neumayer H
BMC Nephrol. 2013; 14:223.
PMID: 24119229
PMC: 3816310.
DOI: 10.1186/1471-2369-14-223.
Glomerular mannose-binding lectin deposition is a useful prognostic predictor in immunoglobulin A nephropathy.
Liu L, Liu N, Chen Y, Wang L, Jiang Y, Wang J
Clin Exp Immunol. 2013; 174(1):152-60.
PMID: 23750697
PMC: 3784222.
DOI: 10.1111/cei.12154.
